TERN - Terns Pharmaceuticals, Inc.
About Terns Pharmaceuticals, Inc. (https://www.ternspharma.com)
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Amy L. Burroughs | Chief Executive Officer & Director | 1971 | $1,173,388 USD |
| Emil T. Kuriakose | Chief Medical Officer | 1981 | $819,800 USD |
| Andrew W. Gengos | Chief Financial Officer & Head of Corporate Development | 1964 | $700,845 USD |
| Melita Sun Jung | Chief Business Officer | 1977 | $508,886 USD |
| Caryn Gordon McDowell | Chief Legal Officer | 1970 | – |
| Debra Sieminski | Senior Vice President of Medical Affairs | – | – |
| James Kanter | Senior Vice President of CMC | – | – |
| Jeffrey R. Jasper | SVP & Senior Distinguished Research Fellow | – | – |
| Robin Andrulevich | Chief People Officer | 1966 | – |
| Scott Harris | Chief Development & Operations Officer | – | – |
| Theresa Clouser | Vice President of Marketing | – | – |
| Yasameen Qazen | Senior Vice President of Regulatory Affairs & Quality Assurance | – | – |